Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD
The Impact of Inhaled Treprostinil on Dyspnea and Exercise Intolerance in Mild COPD; a Pilot and Feasibility Trial
University of Alberta
20 participants
Jun 5, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to: * Perform lung function and exercise tests * Have ultrasound of their heart * Have CT images of their lungs * Visit the lab on 5 different occasions (plus one visit to the CT imaging clinic) The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity
Eligibility
Inclusion Criteria1
- Patients with mild COPD (defined as having a postbronchodilator FEV1/FVC ratio \<0.70 and FEV1 ≥ 80% predicted
Exclusion Criteria5
- Pre-existing heart failure and pulmonary artery hypertension.
- Known thrombocytopenia.
- Resting blood pressure of \<90mmHg systolic and \<50 mmHg diastolic.
- Known sensitivity to prostanoids
- Severe hepatic insufficiency
Interventions
Participants will breathe placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer
Participants will breathe either 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
Participants will breathe either 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06969573